Congrats to all the #MedTwitter folks matching today!! Especially to the new MGH IM Residents matches, welcome!

Residents and fellows at Mass. General Brigham make patients healthier, and unions make our communities stronger. I applaud the MGB Housestaff, who are unionizing through CIR/SEIU and advocating for better working conditions, resources, and dignity in their work.

Congratulations to MGB Housestaff United on organizing their union with CIR/SEIU. I call on Mass General Brigham to hold a fair and transparent election that is free from intimidation.

Congratulations to MGB Housestaff United residents, interns and fellows for organizing to form a union with CIR/SEIU! I stand with these workers in their fight for better wages, benefits and work conditions. wgbh.org/news/local-new…

Beyond grateful to have had the opportunity to pursue residency at MassGeneral Medicine with the incredible mentors and coresidents at MGH IM Residents—so much growth and learning over the last few years. Per my superlative, maybe one day I’ll put these lessons to use in my Ibiza-based lab 😂

So excited to start heme/onc fellowship Dana-Farber / Mass General Cancer Center with this phenomenal crew! Grateful to my family, friends & mentors Stanford Department of Medicine Ronald Witteles Joel W. Neal, MD, PhD Han Zhu Heather Wakelee for helping me reach this next stage of my career

56 FDA/CDER novel drug approvals in 2023 (+51% from 2022) Accelerated approval: 9 Orphan drug designations: 18 Fast track designation: 16 Priority review: 24 Breakthrough therapy: 9

Disgusting.

No doubt the best GI Onc division on the planet! So grateful to work with brilliant, kind, and visionary colleagues #ASCO25 Dana-Farber Dana-Farber News Dana-Farber's Young-Onset Colorectal Cancer Center ASCO

So many important, practice-changing presentations at #ASCO25, but the best part was seeing the work of my incredible Dana-Farber co-fellows 🌟🌟🌟 Sara Khosrowjerdi Char, MD Sarah Waliany, MD, MS Tess O'Meara, MD, MHS Ashley Odai-Afotey, MD

Happy to have contributed to this new work from Kathleen Mulvaney and The Sellers Lab, showing that KRAS and PRMT5 inhibitors synergy, out now in Cancer Research. KRAS/PRMT5 combos ($RVMD/$TNGX) are now in clinical trials, and results couldn't come sooner! doi.org/10.1158/0008-5…